Abstracts tagged "Rheumatoid Factor"

Abstract Number: 372 • 2014 ACR/ARHP Annual Meeting
Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain
Raashid Luqmani¹, Klara Morsley², Anne Miller³, Christopher J. Edwards⁴, M. Kassim Javaid⁵, Daniel Prieto-Alhambra⁶, Rafael Pinedo-Villanueva^7,8, Manuel Medina Peralta⁹, Sebastian Calero Munoz⁹, Nigel Arden^10,11, Francesc Fina-Aviles⁹ and Cyrus Cooper¹², ¹Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom, ²Oxford University Hospitals NHS Trust, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ³Rheumatology, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ⁴University Hospital Southampton, Southampton, United Kingdom, ⁵Rheumatology, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁶NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom, ⁷NDORMS, University of Oxford, Oxford, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁹Institut Català de la Salut, Barcelona, Spain, ¹⁰NIHR Musculoskeletal Biomedical Research Unit University of Oxford, Oxford, United Kingdom, ¹¹University of Southampton, Southampton, United Kingdom, ¹²MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom
Background/Purpose: To assess the sensitivity, specificity, and predictive values of rheumatoid factor (RF) as a test for rheumatoid arthritis (RA) in primary care, and to…
Abstract Number: 2021 • 2014 ACR/ARHP Annual Meeting
The Association Between Rheumatoid Factor and Cardiovascular Disease in Healthy Adults
Chisun Min¹, Mitsumasa Kishimoto¹, Gautam A. Deshpande², Shunya Kaneshita¹, Masei Suda¹, Yuri Ohara¹, Yoichiro Haji¹, Ryo Rokutanda¹, Yasuhiro Suyama¹, Hisanori Shimizu¹, Tokutaro Tsuda¹, Ken-ichi Yamaguchi¹, Akira Takeda³, Yukio Matsui¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, ³Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan
Background/Purpose Rheumatoid arthritis (RA) has been shown to be a risk factor for cardiovascular disease (CVD). Both elevated rheumatoid factor (RF) and anti-citrullinated protein antibodies…
Abstract Number: 1560 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis
Frank Behrens^1,2, Michaela Koehm^2,3, Eva C. Scharbatke⁴, Bianca Wittig⁵, Marc Schmalzing⁴, Holger Gnann⁶, H M Lorenz⁷, Diamant Thaci⁸ and Harald Burkhardt^1,9, ¹Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ²Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ³Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁴Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁷University Hospital Heidelberg, Heidelberg, Germany, ⁸Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lübeck, Germany, ⁹Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany
Background/Purpose Osteoporosis is an important comorbidity in patients with rheumatic diseases, but risk factors for osteoporosis in Psoriatic Arthritis (PsA) patients have not been explored. …
Abstract Number: 1404 • 2014 ACR/ARHP Annual Meeting
Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis
Muhammad Imran¹, Shanley O'brien², Mark Hamblin³ and Mehrdad Maz⁴, ¹Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Internal Medicine, Kansas University Medical Center, Kansas city, MO, ³Pulmonary and Critical Care Medicine, ILD Clinic, Kansas University Medical Center, Kansas city, MO, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Interstitial lung disease (ILD) can be idiopathic or associated with underlying etiologies including rheumatoid arthritis (RA). The purpose of this study is to determine…
Abstract Number: 2394 • 2013 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Smoking Is Not Primarily Associated With Anti-Citrullinated Protein Antibodies, But With The Presence Of Multiple Autoantibodies
Ammar Muhammad¹, Tineke van Wesemael², Yuta Kochi³, Maria Mjaavatten⁴, Kirsten Wevers-de-Boer¹, Cornelia F. Allaart¹, Leendert A. Trouw¹, Akari Suzuki³, Kazuhiko Yamamoto⁵, Annette H.M. van der Helm-van Mil¹, Tom W.J. Huizinga¹, René E.M. Toes¹ and Diane van der Woude¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Smoking is associated with the presence of several autoantibodies in various autoimmune diseases. In rheumatoid arthritis (RA), smoking has been described to be specifically…
Abstract Number: 2291 • 2013 ACR/ARHP Annual Meeting
Only Rheumatoid Factor-Positive Subset Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis Seroconverts To Anti-Citrullinated Peptide/Protein Antibody-Positive
Ryosuke Hiwa¹, Koichiro Ohmura¹, Shuichiro Nakabo¹, Chikashi Terao², Ran Nakashima¹, Yoshitaka Imura³, Naoichiro Yukawa⁴, Hajime Yoshifuji¹, Motomu Hashimoto⁵, Moritoshi Furu⁶, Hiromu Ito⁶, Takao Fujii⁶ and Tsuneyo Mimori^1,6, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: 216 (17.3%) out of 1,246 RA patients were negative for ACPA. In 149 cases of the ACPA-negative RA whose ACPA were measured more than…
Abstract Number: 2298 • 2013 ACR/ARHP Annual Meeting
Upper-Half Serum IgA (20+ TU/ml) and IgM (10+ IU/ml) Levels Significantly Predicted The Long-Term (mean 12 yrs) Onset Of Rheumatoid Arthritis When Combined, But Neither test Individually In Their Respective Full Ranges Of Values
Alfonse T. Masi¹, Azeem A. Rehman¹, Jean C. Aldag¹, Huaping Wang², Ned J. Goertzen³ and Marius C. Teodorescu⁴, ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, IL, ³University of Illinois College of Medicine at Peoria, Peoria, IL, ⁴Microbiology, TheraTest Laboratories Inc, Lombard, IL
Background/Purpose: Serum rheumatoid factor (RF) is a major predictor of the new onset of rheumatoid arthritis (RA). In very early arthritis patients, higher titers…
Abstract Number: 2303 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Rheumatoid Factor-Positive Or Negative Subsets Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis
Ryosuke Hiwa¹, Koichiro Ohmura¹, Noriyuki Yamakawa¹, Moritoshi Furu², Chikashi Terao³, Ran Nakashima¹, Yoshitaka Imura⁴, Naoichiro Yukawa⁵, Hajime Yoshifuji¹, Motomu Hashimoto⁶, Hiromu Ito², Takao Fujii² and Tsuneyo Mimori^1,2, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ⁴Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁶The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Although anti-citrullinated peptide/protein antibody (ACPA) is a specific autoantibody for rheumatoid arthritis (RA), ~20% of RA are ACPA negative. It has been reported that…
Abstract Number: 2267 • 2013 ACR/ARHP Annual Meeting
The Diagnostic Accuracy Of Rheumatoid Factor Testing In Primary Care
Anne Miller¹, Alison L Nightingale², Cormac J Sammon³, Tim Holt⁴, Kamal R Mahtani⁵, Neil McHugh⁶, Corinne S de Vries³ and Raashid A. Luqmani^1,7, ¹Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ²Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁴Primary Health Care Sciences, University of Oxford, Oxford, United Kingdom, ⁵Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom, ⁶Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom
Background/Purpose: Studies of the diagnostic utility of rheumatoid factor (RF) testing for rheumatoid arthritis (RA) conducted in early arthritis clinics in secondary care have reported…
Abstract Number: 1786 • 2013 ACR/ARHP Annual Meeting
91% Of Early RA Patients Are Positive For Serum 14-3-3η Or Its Auto-Antibodies
Walter P. Maksymowych¹, Dirkjan van Schaardenburg², Désirée van der Heijde³, Robert Landewé⁴, Gilles Boire⁵, Maarten Boers⁶, Vivian P. Bykerk⁷, Edward C. Keystone⁸, Katherine A. Siminovitch⁹, Mairead Murphy¹⁰ and Anthony Marotta¹¹, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Jan van Breemen Research Institute | Reade, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Int Med/Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁸Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Augurex Life Sciences Corp., North Vancouver, BC, Canada, ¹¹Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Current serological markers such as RF and ACPA are useful for early diagnosis and perhaps for screening people at risk, but there remains a…
Abstract Number: 1395 • 2013 ACR/ARHP Annual Meeting
CXCL13 Is Elevated In Early and In Established Seropositive Rheumatoid Arthritis and Correlates With Rheumatoid Factor Levels
Jonathan D. Jones¹, B. JoNell Hamilton², Greg Challener³, Artur Fernandes⁴, Pierre Cossette⁵, Patrick Liang⁴, Ariel Masetto⁶, HA Menard⁷, Nathalie Carrier⁸, Gilles Boire⁴ and William Rigby⁹, ¹Rheumatology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ²Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ³Rheumatology, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Rheumatology, McGill University, Montréal, QC, Canada, ⁸Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: CXCL13 is a B cell chemokine whose expression has been reported to be elevated in serum and synovium from patients with rheumatoid arthritis (RA). …
Abstract Number: 1320 • 2013 ACR/ARHP Annual Meeting
Categorization Of Rheumatoid Arthritis Subjects By Rheumatoid Factor and Anti-Cyclic Citrullinated Autoantibody Status Identifies Rheumatoid Arthritis Subjects With Different Characteristics
Swati Modi¹, Mariely Nieves-Plaza², Donald M. Jones³, Erich R Wilkerson⁴, Christine L. Amity⁵, Kelly A. Reckley⁶, Ilinca D. Metes⁷, Jason Lyons⁸, Heather Eng⁹, Stephen R. Wisniewski⁹ and Marc C. Levesque¹⁰, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Rheumatology & Clinical Immun, Univ of Pittsburgh, Pittsburgh, PA, ⁶Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁹Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ¹⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated cyclic peptide (CCP) antibodies have been used to diagnose rheumatoid arthritis (RA) patients, although there is substantial heterogeneity among…
Abstract Number: 1309 • 2013 ACR/ARHP Annual Meeting
Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis
Lillian J. Barra¹, Janet E. Pope², Boulos Haraoui³, Carol A. Hitchon⁴, J. Carter Thorne⁵, Edward C. Keystone^6,7, Diane Tin⁸, Gilles Boire⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ³Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) are believed to be associated with more severe clinical outcomes; however, studies in Early Inflammatory Arthritis…
Abstract Number: 1158 • 2013 ACR/ARHP Annual Meeting
Decreased NK-Cell Numbers and Upregulation Of Markers Of Systemic Inflammation In Autoantibody –Positive Arthralgia Patients and Early Rheumatoid Arthritis Patients But Not In Autoantibody-Negative Rheumatoid Arthritis Patients
Paulina Chalan¹, Johan Bijzet², Kornelis S.M. van der Geest¹, Bart-Jan Kroesen³, Annemieke M.H. Boots^4,5 and Elisabeth Brouwer¹, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Dept. of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Groningen Research initiative on healthy Ageing and Immune Longevity (GRAIL), Groningen, Netherlands
Background/Purpose: Identification of seropositive individuals at risk for arthritis development would open opportunities for early clinical intervention. In a recent study on seropositive arthalgia patients…
Abstract Number: 870 • 2013 ACR/ARHP Annual Meeting
How To Predict That Early Arthritis Without Rheumatoid Factor and ACPA Becomes Rheumatoid Arthritis According To ACR/EULAR 2010 After a 3-Years Follow-Up? Results From The Espoir Cohort
Gaël Mouterde¹, Cédric Lukas², Nathalie Rincheval³, Alain Saraux⁴, Philippe Dieude⁵ and Bernard Combe⁶, ¹Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, ²Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ³Institut Universitaire de Recherche Clinique, Montpellier, France, ⁴Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, ⁵Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ⁶Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France
Background/Purpose: To describe disease course of patients without rheumatoid factor (RF) and anti-citrullinated protein auto-antibodies (ACPA) in an inception cohort of early arthritis patients. To determine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].